OSE Immunotherapeutics shares continued to soar on the Paris Bourse on Wednesday morning, to such an extent that the stock had to be held back for a while in the face of the rush of buyers for the stock.

At around 11:30 a.m., its share price was up by a further 25%, having already gained over 61% the previous day, corresponding to a gain of 102% in two days.

This stock market frenzy follows the publication, on Monday evening, of positive phase 3 results for Tedopi, the company's cancer vaccine, in the journal 'Annals of Oncology'.

According to these data, Tedopi significantly reduced the risk of death by 41% in patients with advanced or metastatic non-small cell lung cancer (NSCLC) in third-line treatment.

A one-year overall survival rate of 44.4% was also observed in these patients, already heavily treated, compared with 27.5% with chemotherapy

"Beyond the confirmation of Tedopi's potential as a cancer vaccine, what has enabled this spectacular progress is the extensive media coverage, with KOLs in particular discussing the prospects and hope that Tedopi represents in the immunotherapy landscape", explain analysts at Invest Securities.

While the success of a biotech depends on a multitude of factors, it depends on its ability to attract the key opinion leaders (KOLs) in its sector, who are often doctors, professors or researchers recognized within their discipline.

We believe that this presentation will help to further highlight Tedopi's potential in certain NSCLC patients within the scientific community and among investors, and we look forward to the start of the new phase 3 trial scheduled for 2024", adds David Seynnaeve, analyst at Degroof Petercam.

Copyright (c) 2023 CercleFinance.com. All rights reserved.